Every 10-Q that MiNK Therapeutics, Inc. (INKT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow INKT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INKT filings page.
MiNK Therapeutics, Inc. reported a Q2 2026 net loss of $3.1 million, narrower than $4.2 million a year earlier, as research and development expense was $1.9 million and general and administrative expense declined to $1.3 million. For the first six months, net loss was $5.9 million versus $7.0 million in 2025.
Cash and cash equivalents were $8.8 million at June 30, 2026, after using $3.8 million in operating cash and repaying a $5.0 million related-party convertible note in January 2026. The company raised $4.4 million by selling 313,478 shares under its at-the-market equity program, with $30.6 million of capacity remaining.
Accumulated deficit reached $162.5 million, and MiNK reported stockholders’ deficit of $14.0 million alongside $16.1 million due to related parties that Agenus has agreed not to call for repayment for the foreseeable future. Management states that, despite expected funding, substantial doubt exists about the company’s ability to continue as a going concern for one year after the report date.
MiNK Therapeutics, Inc. reported a net loss of $2.7 million for the three months ended March 31, 2026, similar to the prior-year period. Research and development expense was $1.2 million while general and administrative expense rose to $1.7 million, mainly from higher share-based compensation and professional fees.
Cash and cash equivalents were $9.5 million as of March 31, 2026, and the company has an accumulated deficit of $159.4 million. It raised about $3.0 million via at-the-market stock sales in the quarter and an additional $150,000 afterward, and repaid a $5.0 million related-party convertible note in January 2026. Management states that while existing cash plus anticipated funding are expected to cover more than one year of liquidity needs, completion of funding is not fully within its control, so substantial doubt exists about its ability to continue as a going concern.
MiNK Therapeutics (INKT) filed its Q3 2025 10‑Q, reporting continued losses and a going concern disclosure. Net loss was $2.89M for the quarter and $9.89M year‑to‑date. Cash and cash equivalents were $14.28M as of September 30, 2025.
The company raised liquidity via its at‑the‑market program, selling about 488,000 shares in Q3 for net proceeds of $13.14M, and an additional ~88,000 shares for $1.2M through November 13, 2025. A related party convertible note carried $5.0M principal and ~$154,000 accrued interest, with fair value of ~$5.7M at quarter‑end. Due to related parties totaled $15.04M.
Operating expenses reflected R&D of $1.14M and G&A of $1.85M for Q3. Net cash used in operations was $3.85M for the nine months. The company executed a 1‑for‑10 reverse stock split effective January 28, 2025, regained Nasdaq MVLS compliance on July 28, 2025, and is no longer a Nasdaq “Controlled Company.” Shares outstanding were 4,694,155 as of November 13, 2025. Management states substantial doubt exists about continuing as a going concern for one year after filing, while pursuing financing and partnerships.
MiNK Therapeutics (INKT) reported operational and financing updates in its Form 10-Q. The company completed an Option Exchange that re-priced 647,915 options to an exercise price of $7.43 with a 10-year term and unchanged vesting, producing approximately $0.6 million of incremental share-based compensation expense ($0.4 million recognized immediately and $0.2 million over the remaining vesting period). Agenus-related intercompany activities are disclosed, including a $14.5 million note receivable as of June 30, 2025 that Agenus agreed not to require repayment for the foreseeable future; interest accrues and may convert at Agenus’ election into equity at 80% of a qualified financing price. The company completed a 1-for-10 reverse stock split effective January 28, 2025. Nasdaq compliance for Minimum Value of Listed Securities was restored after MVLS exceeded $35.0 million for the required consecutive period. Clinical highlights include a durable complete remission in a refractory metastatic testicular cancer patient and a durable partial response in an advanced gastric cancer patient following agenT-797 plus checkpoint blockade.